Transgenic non-human animals expressing a truncated activin type II receptor

a technology of truncated activin and non-human animals, which is applied in the field of gdf8 (myostatin) receptors, can solve the problems of morbidity and mortality, increasing the amount of time, effort and money spent in the united states by individuals intent on losing weight, and becoming a major problem among the pediatric population. it can increase myostatin signal transduction, reduce or inhibit myostatin signal transduction

Inactive Publication Date: 2005-11-17
THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
View PDF10 Cites 131 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0064] A functional peptide portion of a myostatin prodomain that can specifically interact with myostatin, or a functional peptide portion of another GDF prodomain, also can be identified using any of various assays known to be useful for identifying specific protein-protein interactions. Such assays include, for example, methods of gel electrophoresis, affinity chromatography, the two hybrid system of Fields and Song (Nature 340:245-246, 1989; see, also, U.S. Pat. No. 5,283,173; Fearon et al., Proc. Natl. Acad. Sci., USA 89:7958-7962, 1992; Chien et al., Proc. Natl. Acad. Sci. USA 88:9578-9582, 1991; Young, Biol. Reprod. 58:302-311 (1998), each of which is incorporated herein by reference), the reverse two hybrid assay (Leanna and Hannink, Nucl. Acids Res. 24:3341-3347, 1996, which is incorporated herein by reference), the repressed transactivator system (U.S. Pat. No. 5,885,779, which is incorporated herein by reference), the phage display system (Lowman, Ann. Rev. Biophys. Biomol. Struct. 26:401-424, 1997, which is incorporated herein by reference), GST / HIS pull down assays, mutant operators (WO 98 / 01879, which is incorporated herein by reference), the protein recruitment system (U.S. Pat. No. 5,776,689, which is incorporated herein by reference), and the like (see, for example, Mathis, Clin. Chem. 41:139-147, 1995 Lam, Anticancer Drug Res. 12:145-167, 1997; Phizicky et al., Microbiol. Rev. 59:94-123, 1995; each of which is incorporated herein by reference).

Problems solved by technology

The amount of time, effort and money spent in the United States each year by individuals intent on losing weight is staggering.
Obesity, which is defined a being at least about twenty percent above the mean level of adiposity, has dramatically increased in prevalence over the past few decades and is becoming a major problem among the pediatric population.
Obesity and the medical problems directly attributable to it are a major cause of morbidity and mortality throughout the world.
Obesity is a major risk factor for the development of various pathologic conditions, including atherosclerosis, hypertension, heart attack, type II diabetes, gallbladder disease, and certain cancers, and contributes to premature death.
In contrast to the medical problems associated with obesity, the severe weight loss that commonly occurs in patients with certain chronic diseases also presents a challenge to medical intervention.
It is clear, however, that cachexia complicates management of such diseases and is associated with a poor prognosis for the patients.
Progress in using leptin for treating obesity has been slow, however, and, thus far, leptin has not met initial expectations.
Treatment of the morbidly obese currently is limited to surgery to remove portions of the intestine, thereby reducing the amount of food (and calories) absorbed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transgenic non-human animals expressing a truncated activin type II receptor
  • Transgenic non-human animals expressing a truncated activin type II receptor
  • Transgenic non-human animals expressing a truncated activin type II receptor

Examples

Experimental program
Comparison scheme
Effect test

example 1

Myostatin Acts in a Dose Dependent Manner

[0248] This example demonstrates that the activity of myostatin in inhibiting muscle growth is dependent on the level of myostatin expression in vivo.

[0249] Myostatin is a negative regulator of skeletal muscle mass (McPherron et al., supra, 1997; McPherron and Lee, supra, 1997). Myostatin knock-out mice that were homozygous for a deletion of the myostatin gene had a 25-30% increase in total body mass. An examination of the homozygous knock-out mice revealed that the increased muscle mass was due to about a 100-200% increase in skeletal muscle mass throughout the body.

[0250] Mice that were heterozygous for the myostatin mutation also had an increase in total body mass. However, the increase mass of the heterozygotes was less than that of the homozygotes, and was statistically significant in only one age and sex group among the many examined. In order to determine whether heterozygous mice have an intermediate phenotype between that of wild ...

example 2

Myostatin Effect Decreases with Age in Knock-Out Mice

[0252] This example demonstrates that a decreased difference in body weight between wild type mice and homozygous myostatin knock-out mice is associated with a decline in muscle weight of the mutant mice.

[0253] Myostatin knock-out mice weighed approximately 25-30% more than wild type mice at five months of age (McPherron et al., supra, 1997). However, this difference in total body weights became significantly smaller or disappeared altogether as the animals aged. In order to determine whether this effect was due to a relative loss of weight in the knock-out mice due, for example, to muscle degeneration, or to a relatively greater weight gain by wild type mice, a detailed analysis of muscle weights was made as a function of age.

[0254] At all ages examined from 2 months to 17 months, the pectoralis muscle weighed significantly more in homozygous mutant mice than in wild type littermates. The most dramatic difference was observed ...

example 3

Myostatin Affects Fat Accumulation in a Dose Dependent Manner

[0255] This example demonstrates that myostatin knock-out mice fail to accumulate fat, and that the decrease in fat accumulation is associated with the level of myostatin expression in vivo.

[0256] Since the decline in muscle weights in myostatin mutants, as demonstrated in Example 2, did not fully account for the observation that the wild type animals eventually weighed about the same as the mutant mice, the amount of fat accumulation in wild type and mutant mice was examined. The inguinal, epididymal and retroperitoneal fat pads in male mice were examined. There was no difference in the weights of any of these fat pads between wild type and mutant mice at two months of age. By 5 to 6 months of age, wild type and heterozygous knock-out mice both exhibited a large range of fat pad weights, and, on average, fad pad weights increased by approximately 3-fold to 5-fold by the time the animals reached 9 to 10 months of age. Du...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
Login to view more

Abstract

The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject. The invention also provides a method of modulating the growth of muscle tissue or adipose tissue in a eukaryotic organism by administering an agent that affects myostatin signal transduction to the organism.

Description

RELATED APPLICATION DATA [0001] This application is a continuation-in-part of U.S. Ser. No. 09 / 626,896, filed Jul. 27, 2000; which is a continuation-in-part of U.S. Ser. No. 09 / 485,046, filed Jan. 31, 2000; which is based on International Application PCT / US98 / 15598, filed Jul. 28, 1998; which claims the benefit of U.S. Provisional Application Ser. No. 60 / 054,461, filed Aug. 1, 1997 (now abandoned), the entire contents of each of which is incorporated herein by reference.GOVERNMENT SUPPORT [0002] This invention was made in part with government support under Grant No. RO1HD35887 awarded by the National Institutes of Health. The government has certain rights in this invention.FIELD OF THE INVENTION [0003] The invention relates generally to growth differentiation factor (GDF) receptors, and more specifically to GDF-8 (myostatin) receptors, to compositions that affect myostatin signal transduction in a cell, and to methods of using such compositions to modulate myostatin signal transduct...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A01K67/027A61P3/04A61P3/06C07K14/47C07K14/475C07K14/71C12N5/02C12N5/10C12N5/22C12N15/09C12N15/18C12N15/85G01N33/74
CPCA01K67/0271A61K38/1709A01K67/0276A01K67/0278A01K2207/15A01K2217/00A01K2217/05A01K2217/075A01K2217/20A01K2227/105A01K2227/30A01K2267/02A01K2267/03A01K2267/0306A01K2267/0362C07K14/4703C07K14/475C07K14/71C12N15/8509C12N2800/30C12N2830/002C12N2830/008C12N2830/85G01N33/74G01N2333/495G01N2500/00A61K38/00A01K67/0275A61P1/14A61P21/00A61P21/04A61P21/06A61P25/28A61P3/04A61P35/00A61P3/06A61P43/00A61P9/12A61P3/10A01K67/027C12N15/09C12N15/63A22C18/00
Inventor LEE, SE-JINMCPHERRON, ALEXANDRA
Owner THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap